Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FK 33-824 is a **synthetic analog of methionine-enkephalin** designed to provide longer-lasting and more potent analgesic effects than natural enkephalins. It is a pentapeptide with the sequence D-Ala2, N-Me-Phe4, Met(O)-ol5-enkephalin. FK 33-824 acts primarily as a **selective agonist at the μ-opioid receptor** (mu-opioid receptor), with less affinity for the delta-opioid receptor and negligible affinity for kappa-opioid receptors. It produces morphine-like analgesic effects by stimulating opioid receptors, shows cross-tolerance with morphine, can induce dependence, and its effects are antagonized by naloxone. FK 33-824 has been shown to increase pain tolerance in humans, alter gastrointestinal motility, and affect endocrine and metabolic responses. It has been studied clinically but is not known to be marketed as a therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FK 33-824.